Millions of people around the world are suffering from a number of neurodegenerative disorders.
And the number is increasing in an alarming rate.
Neurodegenerative disease is not a single disease, but a complex syndrome with multi-factorial causes.
Our platform will screen and identify each patient with their specific traits.
Each patient should be studied and evaluated in order for them to receive personalized and tailor-made medicine for better and efficient treatment.
Our platform is also developing a multitude of drug candidates with an effective and patient-friendly drug delivery model such as intranasal administration.
Our mission is to make available effective disease-modifying drugs for the patients with highly unmet neurodegenerative disorders.

Our Science
- Excellent Animal Proof of Concept
- Multiple mechanism of actions (MOAs)
- Precision Medicine
- Patient-focused Model

Contact Us
Your opinion is important for us to understand and address these challenging neurodegenerative diseases. Please drop us a message if you are interested in learning more of our science and drug development program.
Press Releases
22 Aug 2022
20 Jul 2021
EINPRESSWIRE
FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JV
09 Apr 2021
09 Apr 2021
26 Mar 2021
Parkinson’s News Today
Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s
18 Jan 2022
24 Mar 2021
Yahoo Finance
Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson’s disease with the US FDA